A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph node transfer for the treatment of patients with secondary lymphedema associated with the treatment of breast cancer
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2018
At a glance
- Drugs AdVEGF-Herantis (Primary)
- Indications Lymphoedema
- Focus Therapeutic Use
- Acronyms AdeLE
- Sponsors Herantis Pharma
- 13 Jun 2018 According to an Herantis Pharma media release, Anne Saarikko, MD, PhD, is the Principal Investigator of the study. By the end of 2018, 2-3 additional hospitals in Sweden and Finland are planned to start enrolling patients.
- 18 May 2018 Status changed from planning to recruiting.
- 08 Feb 2018 According to a Herantis Pharma media release, clinical trial application for this trial has been submitted to the regulatory authorities.